greater number of patients will be unable to complete the intended course of adjuvant therapy for similar reasons. 7 , 8 The administration of chemotherapy with or without radiation therapy (RT) before surgical resection is an alternative strategy that
Search Results
Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung
Daniel G. Coit and Anthony J. Olszanski
considered at high risk for recurrence after adjuvant therapy, interferon-alfa appears to confer a small benefit. The value of high-dose interferon was first established in 1996 by Kirkwood et al. 5 for patients with T4 lesions or evidence of regional
Jennifer A. Ligibel
the completion of adjuvant therapy. Thus, physical activity has been shown to have several benefits for patients with breast cancer both during and after adjuvant therapy. No clear consensus exists on the “best” type of physical activity, but
Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng
in endometrial carcinoma: overview of randomised trials . Clin Oncol (R Coll Radiol) 2008 ; 20 : 463 – 469 . 56 Fleming G . Adjuvant therapy for high-risk adenocarcinoma of the uterus . ASCO Educational Book 2008 : 230 – 233
Crystal S. Denlinger and Andrea M. Barsevick
Edited by Kerrin G. Robinson
Fleming T Macdonald J . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma . N Engl J Med 1990 ; 322 : 352 – 358 . 7 de Gramont A Boni C Navarro M . Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy
Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar
for advanced hormone-sensitive breast cancer at the NCCN 23rd Annual Conference. New Adjuvant Therapy Options for Patients With HER2-Positive Cancer Two new adjuvant treatment options for patients with HER2-positive disease are in the 2018 NCCN
Marsha Reyngold, Joyce Niland, Anna ter Veer, Dana Milne, Tanios Bekaii-Saab, Steven J. Cohen, Lily Lai, Deborah Schrag, John M. Skibber, William Small Jr, Martin Weiser, Neal Wilkinson, and Karyn A. Goodman
adjuvant therapy data (n=3). A total of 29 patients received postoperative RT and were excluded from the analysis of factors associated with omission of preoperative RT. The minimum follow-up time was 120 days for all patients. Variables Analyzed
Melinda L. Telli, William J. Gradishar, and John H. Ward
personalize systemic adjuvant therapy choices,” Dr. Ward said. “The available assays have strong prognostic capability, and more data on this are coming.” Among the available assays are the 21-gene panel (Oncotype Dx), the 70-gene panel (MammaPrint), the 50
Margaret A. Tempero, J. Pablo Arnoletti, Stephen Behrman, Edgar Ben-Josef, Al B. Benson III, Jordan D. Berlin, John L. Cameron, Ephraim S. Casper, Steven J. Cohen, Michelle Duff, Joshua D.I. Ellenhorn, William G. Hawkins, John P. Hoffman, Boris W. Kuvshinoff II, Mokenge P. Malafa, Peter Muscarella II, Eric K. Nakakura, Aaron R. Sasson, Sarah P. Thayer, Douglas S. Tyler, Robert S. Warren, Samuel Whiting, Christopher Willett, and Robert A. Wolff
pancreatic cancer, then surgical consultation is recommended. Restaging with high-quality abdominal and chest imaging is also recommended after surgery for resectable disease and before initiation of adjuvant therapy (see page 980). It should also be
Damon Reed, Ragini Kudchadkar, Jonathan S. Zager, Vernon K. Sondak, and Jane L. Messina
observation and serial ultrasonography in selected cases. 59 Role for Adjuvant Therapies in Pediatric Patients With Node-Positive AMP In the United States, high-dose interferon alfa-2b (HDI) and pegylated interferon alfa-2b are the only approved
